Trelagliptin (TRL) is a new antidiabetic drug that administered as a monotherapy for the treatment of diabetes mellitus (type II) and classified as one of dipeptidyl peptidase-4 (DPP-4) inhibitors. This evidence concerns the gene DPP4 and diabetes mellitus.